Abstract. The clinical significance of the proteasome inhibitor MG132 has been examined in numerous human cancer types; however, its influence on the metastasis and progression of pancreatic cancer is yet to be determined. In the present study, the effect of MG132 treatment on pancreatic ductal adenocarcinoma (PDAC) cell lines (SW1990 and PANC-1) was examined. Compared with the control groups, MG132 treatment resulted in higher expression levels of ETS homologous factor (ESE3), a crucial member of the E26 transformation-specific family that is central to various differentiation and development processes in epithelial tissues. MG132 treatment also increased the nuclear translocation of ESE3. Mechanistically, MG132 further inhibited the invasion and migration of PDAC cells by promoting E-cadherin expression, which not only plays an important role in cell-cell adhesion, but is also a direct target of ESE3. Furthermore, subsequent knockdown experiments, using short interfering RNAs, demonstrated that MG132 upregulated E-cadherin via an increase in ESE3 expression. The results of the present study support the hypothesis that MG132 treatment inhibits PDAC metastasis, highlighting the potential of MG132 as a therapeutic agent for the treatment of patients with PDAC.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) exhibits a high propensity for metastasis, and is therefore considered to be a highly lethal human malignancy (1,2) with a low 5-year survival rate of <5% (3) (4) (5) (6) . Previous reports have demonstrated that both transcriptional and translational downregulation of E-cadherin in parental cells initiated epithelial-mesenchymal transition (EMT), consequently promoting metastasis (7) (8) (9) . The inhibition of adhesion between epithelial cells (cell-cell adhesion) is known to be an essential step during the early stage of tumor metastasis, and typically involves the downregulation of E-cadherin expression (10, 11) .
The ubiquitin-proteasome pathway is associated with the degradation of regulatory proteins that influence DNA repair, signal transduction and apoptosis, and therefore, the proteasome represents a promising target for cancer therapy (12, 13) . MG132 is a well-characterized proteasome inhibitor that induces caspase-8-dependent osteosarcoma-cell apoptosis (14) . Moreover, MG132 was reported to inhibit the transcriptional activity and expression of the oncogenic transcription factor forkhead box M1, promoting apoptosis in several human cancer types (15) . Similarly, the anti-proliferative effect of MG132 and cisplatin co-administration for the treatment of osteosarcoma xenograft models was superior to the monotherapeutic effect of cisplatin, supporting the potential of MG132/cisplatin for the treatment of patients with osteosarcoma (12) . Additionally, it was discovered that MG132 may upregulate the expression of nuclear factor erythroid 2-related factor 2 and increase proteasome activity via the inhibition of diabetic nephropathy in an animal model (16) . Collectively, the aforementioned results suggest that MG132 affects the growth of numerous solid tumor types, and should consequently be considered as a therapeutic target.
E26 transformation-specific family transcription factor (ESE3) plays a pivotal role in the differentiation and development programs of numerous epithelial tissue types. ESE3 has been reported to bind directly to its target genes with the propensity to regulate EMT, stem-like physiological processes (an increased ability to form spheres, similar to epithelial stem cells) (17) (18) (19) and tumor progression (17, 20) . Therefore, ESE3 is considered as a potential tumor suppressor gene associated with pancreatic cancer. In addition, ESE3 was shown to inhibit the migration and invasion capacities of PDAC cells (both in vitro and in vivo), suggesting that the mechanism behind its regulation of PDAC metastasis may involve the regulation of E-cadherin expression levels at the transcriptional level (21) . In summary, the aim of the present study was to investigate the effect of MG132 on the expression level of E-cadherin and the accumulation of ESE3, and to determine its influence on the migration and invasion abilities of PDAC cells.
Materials and methods
Reagents and short interfering (si)RNAs. Proteasome inhibitor MG132 (cat. no. SML1135) and cycloheximide (CHX; cat. no. C104450) were purchased from Sigma-Aldrich; Merck KGaA. The primary antibodies were purchased from Abcam and include; ESE3 (cat. no. ab24337), E-cadherin (cat. no. ab76055) and β-actin (cat. no. E4D9Z; all Cell Signaling Technology, Inc.) antibodies. To determine the influence of ESE3 expression levels on MG132 activity, ESE3 was knocked down in PANC-1 and SW1990 cells by the transfection of specific siRNAs (ESE3#1 forward, 5'-GCC AGU GGC AUG AAA UUC ATT-3' and reverse, 5'-UGA AUU UCA UGC CAC UGG CTT-3'; and ESE3#2 forward, 5'-CAG CCG AGC UAU GAG AUA UTT-3' and reverse, 5'-AUA UCU CAU AGC UCG GCU GTT-3') and an unrelated silencing sequence was synthesized as a negative control (siNC forward, 5'-lUU CUC CGA ACG UGU CAC GUT T-3' and reverse, 5'-ACG UGAC ACG UUC GGA GAA TT-3'). All siRNAs were purchased from Sangon Biotech Co., Ltd. Stock solutions of MG132 were prepared in DMSO at a concentration of 10 mg/ml and then diluted in cell culture medium to a final working concentration of 10 µM.
Cell culture conditions and pharmacological treatment.
The SW1990 and PANC-1 PDAC cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco; Thermo Fisher Scientific, Inc.) containing 10% fetal bovine serum (FBS, Shanghai ExCell Biology, Inc.) at 37˚C, in a humidified culture chamber with 5% CO 2 . The cells were detached from the culture plates using trypsin (0.05%) and EDTA (0.5 mM) in phosphate-buffered saline (PBS). The cell lines were treated with 10 µM MG132 for 0, 2, 4 and 6 h at 37˚C. Groups of control cells treated with DMSO only were evaluated in parallel to the experimental groups. Cycloheximide (CHX), a protein-synthesis inhibitor, was used to test the degradation of proteins following MG132 and DMSO treatment at 50 µg/ml for 4 h. All experiments were repeated three times.
Inhibitory effects of MG132. The half-maximal inhibitory concentration (IC 50 ) of MG132 on PDAC cells was detected using the Real-Time Cellular Analysis (RTCA) system (ACEA Biosciences, Inc.). DMEM (10% FBS) was added to the E-Plate assay (ACEA Biosciences, Inc.) to determine the background impedance values. Log-phase cells were collected and counted to achieve a suspension of 4x10 3 cells/well; the cells were then added to the E-Plate on a test stand (having been previously incubated at 37˚C and 5% CO 2 ), and left to react at room temperature for 30 min. Real-time dynamic cell-proliferation detection was performed overnight at 37˚C, 5% CO 2 . The MG132 stock solution was added to the corresponding concentration gradient solutions, and real-time dynamic detection was continued. The cell effect curves and IC 50 values were obtained using the RTCA Software (RTCA Software Lite 2.2.1).
Western blotting. The cells were washed with PBS and then lysed using RIPA buffer containing 1% protease inhibitor (both Sigma-Aldrich; Merck KGaA). Equal amounts of protein were then resolved using 10% SDS-PAGE. Protein concentrations were quantified using the Pierce protein assay kit (cat. no. UA269551, Thermo Fisher Scientific, Inc.). The separated proteins (20 µg/lane) were carefully transferred to polyvinylidene fluoride membranes at 4˚C for 2 h. Subsequently the proteins were blocked using 5% skimmed milk (BD Biosciences) and probed with the following primary antibodies: Anti-ESE3 (1:1,000; cat. no. ab24337), anti-E-cadherin (1:1,000; both Abcam; cat. no. ab76055) and β-actin (1:5,000; cat. no. E4D9Z; Cell Signaling Technology, Inc.) for 2 h at room temperature. Following primary incubation, the membranes were incubated with horseradish peroxidase-conjugated goat anti-rabbit (1:10,000; ProteinTech Group, Inc; cat. no. SA00001-2)/anti-mouse secondary antibodies (1:10,000; ProteinTech Group, Inc; cat. no. SA00001-1) for 1 h at room temperature. Protein quantification was performed using Image Lab Software (version 5.2.1, Bio-Rad Laboratories, Inc).
Wound-healing and invasion assays.
For the wound-healing assay, the PANC-1 and SW1990 cells (treated with either MG132 or DMSO) were seeded into a 24-well plate prior to wounding. The wounds were created by scratching across the monolayer using sterile pipette tips. The cells were induced with DMEM containing 1% FBS. After a 48-h incubation in a humidified culture chamber (5% CO 2 ) the cells were imaged using an inverted routine microscope (magnification, x40; ECLIPSE Ts2; Nikon Corporation).
For the invasion assay, 1x10 5 cells were added to the upper chamber of a transwell insert with DMEM containing 1% FBS, and filters coated with Matrigel (1:5 dilution, BD Biosciences) were used. DMEM containing 10% FBS was added to the lower chamber and used as a chemoattractant. The cells were subsequently incubated under controlled conditions (37˚C and 5% CO 2 ) for 18 h. A three-step stain set (Corning Inc.) was used to stain the cells that had migrated to the bottoms of the filters at room temperature (each step was stained for 5 min). Then, 10 different fields of view were randomly selected, and cell counting was performed using an inverted routine microscope (magnification, 40x; ECLIPSE Ts2; Nikon Corporation). The mean cell numbers were calculated and statistical analyses were performed on these values.
Immunofluorescence. To investigate the expression patterns of ESE3 in PDAC cells treated with MG132, 2x10 3 PANC-1 cells were seeded onto glass microscope slides, washed with PBS, and then fixed with 4% paraformaldehyde for 10 min at room temperature. The cells were then permeabilized with 0.3% Triton X-100 in PBS for 5 min at room temperature. To minimize non-specific staining, the cells were treated with 3% bovine serum albumin (Sigma-Aldrich; Merck KGaA) in PBS for 1 h. During the immunolabeling step, an anti-ESE3 antibody (1:100 dilution) was used to stain the cells, overnight at 4˚C. The nuclei of the labeled cells were subsequently stained with 4',6-diamidino-2-phenylindole (DAPI) Fluoromount-G medium (Southern Biotech), and the slides were viewed using a confocal fluorescence microscope (magnification, x200; LSN 880; ZEISS; GmbH).
Statistical analysis. All statistical analyses were performed using GraphPad Prism 7.0 software (GraphPad Software, Inc.). The unpaired Student's t-test or Mann-Whitney U test were used to compare the differences between two groups, and one-way ANOVA followed by the SNK-q test was used to compare ≥3 groups. The results are presented as the mean ± standard error of the mean (SEM) and P<0.05 was considered to indicate a statistically significant result.
Results

Proteasome inhibitor MG132 exhibits cytotoxic effects and inhibits the migration and invasion of pancreatic cancer cells.
After 48 h of treatment, the IC 50 values of MG132 in PANC-1 and SW1990 PDAC cells were 11.20±0.742 and 11.18±0.787 µM, respectively, according to RTCA (Fig. 1A) . Based on this finding, and consistent with previously reported literature (22) , the MG132 concentration was fixed at 10 µM for subsequent experiments.
The effect of MG132 on the invasion cell number of PANC-1 and SW1990 cells was evaluated using Transwell chambers. The number of PANC-1 and SW1990 cells passing through the polycarbonate membrane at 18 h was reduced by 10 µM MG132, compared with that of the DMSO-treated control group (Fig. 1B) . The mean number of invading PANC-1 cells was 105 for the treatment group, compared with 169 for the control group, and the mean number of invading SW1990 cells was 85 for the treatment group, compared with 128 for the control group (P<0.05). The wound-healing assay revealed that the migration of PANC-1 and SW1990 cells was significantly reduced following MG132 treatment. The wound areas for PANC-1 cells were ~12.0±4.1% at 48 h for the MG132-treated group, compared with ~47.2±3.8% for the control group (P<0.01; Fig. 1C ). SW1990-cell wound healing was also significantly suppressed, with wound areas of ~27.6±2.0% at 48 h for the MG132-treated group, compared with ~43.9±2.8% for the control group (P<0.005; Fig. 1C) . The results of the present study suggest that MG132 is able to inhibit the invasion and migration properties of PANC-1 and SW1990 cells.
Degradation of ESE3 via the ubiquitin-proteasome pathway is inhibited by MG132.
To investigate the potential mechanism of MG132-associated suppression of PDAC cell invasion and migration, western blotting and immunofluorescence experiments were performed. Following the treatment of pancreatic cell lines (PANC-1 and SW1990) with 10 µM MG132 for various time periods (0-6 h), the ESE3 expression levels increased in a time-dependent manner ( Fig. 2A and B; P<0.05). To determine whether the observed increase involved an MG132-dependent pathway, 10 µM MG132 was added to PANC-1 and SW1990 cells for 2 h, followed by treatment with CHX (50 µg/ml) for 4 h to inhibit ESE3 protein synthesis. Western blotting determined that ESE3 exhibited high expression levels following MG132 treatment ( Fig. 2C and D; P<0.05) . Thus, it was demonstrated that MG132 increased ESE3 levels via the inhibition of its proteasomal degradation. 
MG132 increases ESE3 nuclear translocation.
Previous studies have determined that ESE3 is primarily localized in the nucleus of normal epithelial esophageal cells (20, 23, 24) . Hence, the nuclear expression of ESE3 was investigated using immunofluorescence in PDAC cells treated with MG132. Fluorescent staining was performed to visualize the expression of ESE3 (Fig. 3A) . Arrowheads indicate the nuclear expression of ESE3 (Fig. 3A) , and the number of arrowheads was determined and compared with the DMSO-treated control group. The nuclear translocation of ESE3 was increased in PANC-1 cells treated with MG132 ( Fig. 3A; P<0.05 ), yet no significant increase was observed in SW1990 cells.
MG132 upregulates E-cadherin expression levels via the upregulation of ESE3.
The results of the present study indicated that treatment with MG132 was associated with increased expression of ESE3 in PDAC cells. To investigate the factors affecting the migration and invasion of PDAC cells down-stream of ESE3, E-cadherin [a classical EMT marker and a direct target of ESE3; (21)] expression levels were determined to be increased in both SW1990 and PANC-1 cell lines, following MG132 treatment (Fig. 4A and B) . However, similar changes were not detected in other EMT-related markers such as N-cadherin or Snail. Additionally, in PANC-1 cells transfected with siESE3, the upregulation of E-cadherin expression caused by MG132 was significantly inhibited (Fig. 4C; P<0.05 ). This suggested that MG132 directly stimulates E-cadherin expression via the increased expression of ESE3.
ESE3-knockdown and low E-cadherin expression reverse the inhibitory effect of MG132 on the migration and invasion abilities of PANC-1 and SW1990 cells.
To assess the influence of ESE3 expression on the migration and invasion capacities of PANC-1 cells treated with MG132, ESE3 expression was knocked down using siESE3 and the effect was analyzed using Transwell and wound-healing assays. The results showed that knockdown of ESE3 expression significantly reduced the inhibitory effect of MG132 on PANC-1 and SW1990 cell invasiveness ( Fig. 5A and B) and migration ( Fig. 5C and D) . These findings suggest that ESE3 is an important target under MG132 treatment conditions.
Discussion
It has been reported that during the early stages of tumor metastasis, it is important to inhibit cell-cell adhesion between epithelial cells (25) (26) (27) . Indeed, inhibition of the cellular adhesion mediated by E-cadherin during this period represents a major step in the treatment of primary tumors, and serves as a classical EMT marker (28) (29) (30) . As a nuclear factor, ESE3 may play a role in this process by directly binding to the promoter of the E-cadherin gene in PDAC cells, thereby stimulating its expression (21) .
In the current study, it was determined that the proteasome inhibitor MG132 inhibited PDAC cell invasion and migration in vitro, which has not been previously reported. To determine the molecular mechanism underlying this process, the expression level of the EMT marker E-cadherin (but not snail or N-cadherin) was evaluated in PDAC cells. E-cadherin expression increased following treatment with MG132. Further investigation indicated that MG132 increased the accumulation of ESE3 by inhibiting its proteasomal degradation. An immunofluorescence assay was performed to investigate MG132-associated promotion of translocation to the nucleus in PANC-1 cells; however, no significant increase was observed in SW1990 cells. Data from the present study indicate that MG132 activated E-cadherin by influencing both the expression level and translocation of ESE3. The addition of CHX demonstrated that the increase in ESE3 levels was not influenced by an increase in protein synthesis. Thus, MG132 suppressed the invasion and migration of two PDAC cell lines by increasing ESE3 expression levels, via the suppression of the relevant proteasome pathway, and its down-stream target, the E-cadherin gene.
Subsequently, the central role of ESE3 in the inhibition of migration and invasion in PDAC cells (which was increased by MG132) was further investigated. ESE3 was knocked down by transfection of PDAC cells with siESE3. The rescue experiment demonstrated that siESE3 reduced MG132-induced inhibition of migration and invasion in PDAC cell lines. This conclusion was further supported by the discovery that MG132 promoted E-cadherin-induced PDAC migration and invasion through the accumulation of ESE3.
Future studies should focus on discovering the specific signaling pathway by which MG132 influences the expression of ESE3, as this may further explain the difference in translocation of ESE3 to the nucleus between PANC-1 cells and SW1990 cells, following MG132 treatment.
Overall, the findings of the present study improve our understanding of the biological function of MG132 in PDAC metastasis. The current results suggest that MG132 may be combined with other chemotherapeutic drugs for the treatment PDAC, in order to block the signaling pathway that downregulates ESE3 expression. By inhibiting PDAC metastasis, this strategy may result in improved patient outcome.
